A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly ...
Jun 4, 2023
0
54
Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years ...
Nov 24, 2011
0
0
When a 41-year-old woman was diagnosed with chronic-phase chronic myeloid leukemia, she received a bone marrow transplant and subsequent leukocyte infusion from her sister. These treatments controlled her leukemia, but seven ...
Dec 12, 2011
0
0
Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors.
Jun 9, 2011
0
0
An international team of scientists in Japan, Switzerland, and the United States has confirmed that combining chemotherapy and immunotherapy in cancer treatment enhances the immune system's ability to find and eliminate cancer ...
Feb 13, 2012
0
0
A new study finds a significant racial disparity within a doubly troubled population of patients: those with HIV and Hodgkin lymphoma. In such cases, blacks are at significantly higher risk than whites of not receiving treatment ...
Jan 8, 2016
0
9
Patients with some types of lymphoma that become resistant to standard treatments may benefit from a therapy that University of Wisconsin–Madison researchers are evaluating after they discovered a key process that fuels ...
Mar 16, 2024
0
48
A study published by researchers from Mayo Clinic Cancer Center at Mayo Clinic in Florida and Case Western, Cleveland Medical Center, investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma ...
May 12, 2022
0
18
Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma (LBCL) ...
Oct 5, 2020
0
35
